Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Vornorexant (ORN-0829; TS-142) is a potent dual OX1R and OX2R antagonist with IC 50 values of 1.05 nM and 1.27 nM, respectively. Vornorexant exhibits potent sleep-promoting effects in vivo and can be used for insomnia treatment research.
产品描述 | Vornorexant (ORN-0829; TS-142) is a potent dual OX1R and OX2R antagonist with IC 50 values of 1.05 nM and 1.27 nM, respectively. Vornorexant exhibits potent sleep-promoting effects in vivo and can be used for insomnia treatment research. |
体内活性 | Vornorexant (oral administration; 1-10 mg/kg) exhibits potent sleep-promoting effects at a po. dose of 1 mg/kg in a rat polysomnogram study. It results in a dose-dependent increase in the percentage of total sleep[1].Vornorexant exhibits optimal PK properties with a rapid T max and short half-lives in rats and dogs. The T 1/2 is 0.238 hours and 1.16 hours, respectively in rat and dog[1]. Animal Model: Rat[1]Dosage: 1, 3, 10 mg/kg Administration: Oral administration to rats prior to turning the light off (start of the active phase); 1-10 mg/kg Result: Possessed promising sleep-inducing and sleep-promoting effects. |
别名 | ORN-0829, TS-142 |
分子量 | 447.474 |
分子式 | C23H22FN7O2 |
CAS No. | 1517965-94-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Vornorexant 1517965-94-4 ORN0829 ORN-0829 TS142 TS-142 TS 142 ORN 0829 Inhibitor inhibitor inhibit